Ailiyaer Y, et al. - The efficiency and adverse effects of nebulized amikacin treatment were determined when administered during exacerbation of bronchiectasis (BE) patients infected with P. aeruginosa. The rate of bacterial eradication from the sputum, drug resistance, and adverse effects was assessed in the intervention group (patients receiving amikacin nebulization (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy) and in the control group (treatment with standard antibiotic therapy alone). In the intervention group vs control group, significantly higher bacterial eradication rate of sputum was noted. Five drug-resistant cases in the intervention group and 7 in the control group were detected. Nebulized amikacin treatment is a safe treatment for exacerbation of BE.